11-Mar-2003 - The Dow Chemical Company

TOPIGEN Pharmaceuticals Inc. signs development and manufacturing agreement with The Dow Chemical Company

TOPIGEN Pharmaceuticals Inc. and The Dow Chemical Company recently signed a joint agreement for Dowpharma, Dow's pharmaceutical manufacturing services business unit, to supply select, proprietary oligonucleotides to TOPIGEN.

TOPIGEN's pharmaceutical development program, based primarily on a unique and synergistic blend of antisense oligonucleotides, is directed toward the treatment of a host of inflammatory respiratory diseases. TOPIGEN's therapeutic platform is predicated on engaging multiple, not single, genes, which significantly broadens the anti-inflammatory response. The effectiveness of this approach has been amply borne out by proof-of-concept trials with TOPIGEN's lead product for the treatment of asthma.

Dowpharma, with its unique and well-grounded combination of oligonucleotide experience, process engineering capabilities and regulatory compliance record will provide a high-quality and reliable source of supply as oligonucleotide-based products move through the phases of clinical trials to commercial production. Dowpharma is currently providing its clients with both laboratory (campaigns to 100g) and mid-scale (campaigns to 5kg) cGMP oligonucleotide development and manufacturing capabilities. A commercial unit (~500kg annual capacity) will be on-line later in 2003.

This collaboration synergizes the strengths of both organizations - TOPIGEN's in the discovery and commercialization of novel therapeutics and Dowpharma in analytical and process development, and scale-up from the laboratory to cGMP commercial production.

Facts, background information, dossiers
  • services
  • scale-up
  • respiratory diseases
  • clinical trials
  • asthma
More about Dow Chemical
  • News

    Evonik and Dow develop industrial-scale direct synthesis of propylene glycol from propylene and hydrogen peroxide

    Dow and Evonik have entered into an exclusive technology partnership. Together, they plan to bring a unique method for directly synthesizing propylene glycol (PG) from propylene and hydrogen peroxide to market maturity. The basis for the method, named HYPROSYN™, has been created over the la ... more

    Dow announces divestiture of its Acetone Derivatives business

    Dow announced that it has reached an agreement for the divestiture of its Acetone Derivatives business to ALTIVIA Ketones & Additives, LLC, an affiliate of ALTIVIA, a privately held producer of chemicals headquartered in Houston, Texas. “This divestiture illustrates Dow’s disciplined approa ... more

    Dow holds groundbreaking ceremony for new silicone resin plant in China

    Dow held a groundbreaking ceremony for a new high-value silicone resin plant to be located at the Company’s manufacturing site in Zhangjiagang, Jiangsu, China. The new facility will significantly expand Dow’s global high-value silicone resin capacity to meet increased demand for the creatio ... more

  • Companies

    The Dow Chemical Company

    With annual sales of $58 billion in 2008 and 46,000 employees worldwide, Dow is a diversified chemical company that combines the power of science and technology with the " Human Element ” to constantly improve what is essential to human progress. The Company delivers a broad range of produ ... more

    Dow Chemical Co

    Philadelphia is the home for Dow’s Advanced Materials Division, which is the umbrella for some of the company’s most important high-growth specialty businesses. Five businesses make up the division – Coatings, Building and Construction, Paper and Textiles, Specialty Packaging and Films, Des ... more